Wall Street brokerages expect Catalent (NYSE:CTLT) to post sales of $610.64 million for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Catalent’s earnings. The lowest sales estimate is $599.58 million and the highest is $622.50 million. Catalent posted sales of $532.60 million in the same quarter last year, which would indicate a positive year over year growth rate of 14.7%. The firm is expected to announce its next quarterly earnings results on Thursday, May 3rd.
On average, analysts expect that Catalent will report full-year sales of $610.64 million for the current year, with estimates ranging from $2.44 billion to $2.47 billion. For the next fiscal year, analysts forecast that the firm will report sales of $2.66 billion per share, with estimates ranging from $2.53 billion to $2.76 billion. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Catalent.
Catalent (NYSE:CTLT) last issued its earnings results on Monday, February 5th. The company reported $0.41 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.10. Catalent had a return on equity of 23.85% and a net margin of 3.03%. The business had revenue of $606.30 million during the quarter, compared to analyst estimates of $565.05 million. During the same quarter in the previous year, the firm earned $0.27 EPS. Catalent’s revenue was up 25.3% on a year-over-year basis.
Shares of NYSE:CTLT opened at $39.00 on Friday. Catalent has a fifty-two week low of $27.48 and a fifty-two week high of $47.87. The company has a quick ratio of 1.78, a current ratio of 2.22 and a debt-to-equity ratio of 2.66. The stock has a market capitalization of $5,298.09, a price-to-earnings ratio of 28.89, a price-to-earnings-growth ratio of 2.30 and a beta of 1.53.
In other news, SVP William Downie sold 9,082 shares of the company’s stock in a transaction dated Thursday, March 8th. The shares were sold at an average price of $41.80, for a total transaction of $379,627.60. Following the completion of the sale, the senior vice president now owns 46,986 shares of the company’s stock, valued at approximately $1,964,014.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.70% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in CTLT. Zions Bancorporation bought a new position in shares of Catalent during the 3rd quarter valued at approximately $100,000. First Bank & Trust grew its stake in shares of Catalent by 54.2% during the 4th quarter. First Bank & Trust now owns 3,764 shares of the company’s stock valued at $155,000 after acquiring an additional 1,323 shares during the period. CAPROCK Group Inc. bought a new position in shares of Catalent during the 4th quarter valued at approximately $203,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp bought a new position in shares of Catalent during the 4th quarter valued at approximately $242,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Catalent by 45.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,325 shares of the company’s stock valued at $301,000 after acquiring an additional 2,282 shares during the period. 99.89% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “$610.64 Million in Sales Expected for Catalent (CTLT) This Quarter” was first published by Week Herald and is the sole property of of Week Herald. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://weekherald.com/2018/04/15/610-64-million-in-sales-expected-for-catalent-ctlt-this-quarter.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.